Europe Attracts €25 Billion in Biotech VC, Letta Urges Fifth Freedom
Updated
Updated · Euronews · Jul 7
Europe Attracts €25 Billion in Biotech VC, Letta Urges Fifth Freedom
1 articles · Updated · Euronews · Jul 7
Summary
€25 billion flowed to European biopharma start-ups from 2015 to June 2025, versus €219 billion in the US, underscoring Enrico Letta’s warning that Europe excels at science but fails to scale companies.
That gap is reinforced by a fragmented market: the European Economic Area’s share of global clinical trials fell to 9% in 2023 from 18% in 2013, while China climbed to nearly 30%.
Letta argues the EU needs a “Fifth Freedom” — free movement of knowledge, research and innovation — so start-ups can find capital, talent and manufacturing across the bloc without moving abroad.
He says health and life sciences show the broader risk for Europe: without deeper capital pools and a more unified market, the continent could become a customer for foreign industries rather than a home for its own innovators.
With China's formidable speed and funding, can Europe's new 'fifth freedom' truly close the innovation gap before it is too late?
Beyond new laws, how can Europe persuade its brightest minds to stay when US and Asian opportunities remain so lucrative?
Will EU rules designed to create 'European champions' actually stifle the very mergers needed for them to scale up globally?
Unlocking €1 Trillion in Value: How a Unified European Biotech Market and the “Fifth Freedom” Can Restore Global Competitiveness
Overview
In 2026, the European biotech sector faces a challenging environment as the era of easy capital ends and the market corrects after the post-pandemic boom. Investors are now more selective, focusing on companies with strong clinical progress and clear development plans. This shift has redefined what makes a biotech company fundable, with sharper asset strategies and capable management teams in demand. Despite a sharp drop in UK equity financing, capital still flows to promising firms. The sector’s future depends on adapting to these new investor expectations and building a unified, competitive European biotech market.